Evidence map›Paper›PMID 40170898›Full record

ArticleFrontiers in neurology2025

Prediction model for severe autoimmune encephalitis: a tool for risk assessment and individualized treatment guidance.

Zhuxiao Xie, Jingxiao Zhang, Lei Liu, Enyu Hu, Jiawei Wang

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhuxiao Xie *Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Jingxiao Zhang *Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Lei LiuDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Enyu HuDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Jiawei WangDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe autoimmune encephalitis (AE) can cause significant neurological deficits, status epilepticus, status dystonicus, and even death, which can be life-threatening to patients. Accurate risk stratification for severe AE progression is critical for optimizing therapeutic strategies. The comprehensive prediction models for severe AE based on routine clinical data and laboratory indicators remain lacking. Objective: To develop and validate a prediction model for severe AE to optimize individualized treatment. Methods: We collected clinical data and laboratory examination results from 207 patients with confirmed AE. The study population was divided into development and validation cohort. A prediction model for severe AE was constructed using a nomogram and was rigorously validated both internally and externally. Severe AE was defined as modified Rankin Scale (mRS) > 2 and Clinical Assessment Scale for Encephalitis (CASE) > 4. Results: The variables ultimately included in the nomogram for the severe AE predictive model were age, psychiatric and/or behavioral abnormalities, seizures, decreased level of consciousness, cognitive impairment, involuntary movements, autonomic dysfunction, and increased intrathecal IgG synthesis rate. It demonstrated excellent discriminative capacity and calibration through internal-external validation. Conclusion: The prediction model has highly feasibility in clinical practice, and holds promise as an important tool for risk assessment and guiding individualized treatment in patients with AE.

Indexed as

autoimmune encephalitisindividualized treatmentprediction modelrisk stratificationsevere

Identifiers

PMID40170898
PMCPMC11958171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.